Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
DoorDash to Acquire Maplebear in $17 Billion Cash, Stock Transaction

DoorDash to Acquire Maplebear in $17 Billion Cash, Stock Transaction

MT newswireMT newswire2026/10/29 11:48
07:48 AM EDT, 10/29/2026 (MT Newswires) -- DoorDash (DASH) signed a definitive deal to acquire Maplebear (CART), also known as Instacart, for $65 per Instacart share, or an equity value of about $17 billion, the companies said Thursday. Under the deal, Instacart shareholders may choose to receive $65 in cash or 0.3372 of a DoorDash common share, or a mix of $48.75 in cash and 0.0843 shares of DoorDash, according to the statement. The stock consideration is capped at 25% of the total deal value, the companies said. DoorDash expects to fund the purchase with existing cash and debt financing, backed by a financing commitment letter with JPMorgan Chase Bank, the companies said. The companies said they expect to close the transaction at the end of 2027 or H1 2028. Shares of DoorDash were up more than 8%, while Maplebear stock was down more than 1% premarket Thursday.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12